CN100500211C - 用凝血酶派生的肽的治疗方法 - Google Patents

用凝血酶派生的肽的治疗方法 Download PDF

Info

Publication number
CN100500211C
CN100500211C CNB018154581A CN01815458A CN100500211C CN 100500211 C CN100500211 C CN 100500211C CN B018154581 A CNB018154581 A CN B018154581A CN 01815458 A CN01815458 A CN 01815458A CN 100500211 C CN100500211 C CN 100500211C
Authority
CN
China
Prior art keywords
thrombin
gly
peptide
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018154581A
Other languages
English (en)
Chinese (zh)
Other versions
CN1455678A (zh
Inventor
达芮尔·H·卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capstone Holding Corp
Original Assignee
Osorogis Ltd
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osorogis Ltd, University of Texas System filed Critical Osorogis Ltd
Publication of CN1455678A publication Critical patent/CN1455678A/zh
Application granted granted Critical
Publication of CN100500211C publication Critical patent/CN100500211C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CNB018154581A 2000-07-12 2001-07-12 用凝血酶派生的肽的治疗方法 Expired - Fee Related CN100500211C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21758300P 2000-07-12 2000-07-12
US60/217583 2000-07-12

Publications (2)

Publication Number Publication Date
CN1455678A CN1455678A (zh) 2003-11-12
CN100500211C true CN100500211C (zh) 2009-06-17

Family

ID=22811661

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018154581A Expired - Fee Related CN100500211C (zh) 2000-07-12 2001-07-12 用凝血酶派生的肽的治疗方法

Country Status (10)

Country Link
US (5) US6867190B2 (cg-RX-API-DMAC7.html)
EP (1) EP1253937B1 (cg-RX-API-DMAC7.html)
JP (2) JP3618736B2 (cg-RX-API-DMAC7.html)
CN (1) CN100500211C (cg-RX-API-DMAC7.html)
AT (1) ATE249238T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001278907B2 (cg-RX-API-DMAC7.html)
CA (1) CA2415778A1 (cg-RX-API-DMAC7.html)
DE (2) DE60100740T4 (cg-RX-API-DMAC7.html)
TW (1) TWI257307B (cg-RX-API-DMAC7.html)
WO (1) WO2002004008A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU2002241917B2 (en) * 2000-07-12 2006-06-15 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
ES2395275T3 (es) * 2002-01-16 2013-02-11 Capstone Therapeutics Corp. Péptidos derivados de la trombina para estimular la reparación del tejido cardíaco
WO2004005317A2 (en) * 2002-07-02 2004-01-15 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
DK1521603T3 (da) * 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
CN103088017B (zh) 2003-02-12 2016-04-13 孟山都技术有限公司 棉花事件mon 88913及其组合物和检测方法
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7291596B2 (en) * 2003-12-31 2007-11-06 Orthologic Corp. Pharmaceutical composition for thrombin peptide derivatives
EP1778652A2 (en) * 2004-08-20 2007-05-02 EntreMed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
JP2006321740A (ja) * 2005-05-18 2006-11-30 Kanazawa Univ 虚血後血管新生促進剤
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
EP2063910A2 (en) 2006-09-22 2009-06-03 Orthologic Corp. Method of treating endothelial dysfunction
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
WO2008124173A1 (en) * 2007-04-10 2008-10-16 The Board Of Regents, The University Of Texas System Combination therapy for cardiac revascularization and cardiac repair
US8202528B2 (en) * 2007-06-05 2012-06-19 Abbott Cardiovascular Systems Inc. Implantable medical devices with elastomeric block copolymer coatings
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
US8586398B2 (en) * 2008-01-18 2013-11-19 Miasole Sodium-incorporation in solar cell substrates and contacts
EP2282754A2 (en) * 2008-03-26 2011-02-16 Orthologic Corp. Method of treating peripheral arterial disease
CA2719940A1 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
AU2009229395A1 (en) * 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
WO2009120304A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
WO2010033862A2 (en) * 2008-09-19 2010-03-25 The Board Of Regents, The University Of Texas System Methods for treating cancer
US20130101574A1 (en) * 2010-06-11 2013-04-25 Darrell H. Carney Methods of using thrombin peptide derivatives
GB201314312D0 (en) * 2013-08-09 2013-09-25 Regentec Ltd Composition and delivery system
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
EP3952991A4 (en) * 2019-04-12 2023-08-09 Affirmed Pharma, LLC RUSALATIDE ACETATE COMPOSITIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003151A2 (en) * 1986-10-31 1988-05-05 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
JPH08508511A (ja) 1993-04-29 1996-09-10 ワシントン・ユニバーシテイー 副行循環の改善への血小板由来成長因子の使用
KR100465222B1 (ko) * 1995-10-24 2005-05-17 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 평활근세포증식억제활성을갖는조직인자응고계인히비터(tfpi)-유래펩티드
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6033436A (en) * 1998-02-17 2000-03-07 Md3, Inc. Expandable stent
BR9909717A (pt) 1998-04-17 2000-12-26 Angiogenix Inc Fatores angiogênicos terapêuticos e métodos para seu uso
AU768330B2 (en) 1998-10-26 2003-12-11 Vegenics Limited Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003151A2 (en) * 1986-10-31 1988-05-05 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5500412A (en) * 1986-10-31 1996-03-19 Carney; Darrell H. Thrombin derived polypeptides; compositions and methods for use

Also Published As

Publication number Publication date
US20060134167A1 (en) 2006-06-22
CA2415778A1 (en) 2002-01-17
EP1253937A2 (en) 2002-11-06
DE60100740T2 (de) 2004-07-01
JP2005036007A (ja) 2005-02-10
AU7890701A (en) 2002-01-21
HK1060302A1 (zh) 2004-08-06
WO2002004008A3 (en) 2002-08-22
DE60100740T4 (de) 2005-01-27
US6861407B2 (en) 2005-03-01
CN1455678A (zh) 2003-11-12
EP1253937B1 (en) 2003-09-10
US7214661B2 (en) 2007-05-08
AU2001278907B2 (en) 2004-10-21
WO2002004008A2 (en) 2002-01-17
JP2004502739A (ja) 2004-01-29
US7732411B2 (en) 2010-06-08
US20050153884A1 (en) 2005-07-14
US20020187933A1 (en) 2002-12-12
US6867190B2 (en) 2005-03-15
ATE249238T1 (de) 2003-09-15
TWI257307B (en) 2006-07-01
DE60100740D1 (de) 2003-10-16
US20080131474A1 (en) 2008-06-05
JP3618736B2 (ja) 2005-02-09
US20020061852A1 (en) 2002-05-23
US7034001B2 (en) 2006-04-25

Similar Documents

Publication Publication Date Title
CN100500211C (zh) 用凝血酶派生的肽的治疗方法
AU2001278907A1 (en) Methods of therapy with thrombin derived peptides
JP3639593B2 (ja) 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤
US6544541B1 (en) Devices and compounds for treating arterial restenosis
US20060115457A1 (en) Biocompatible hydrogel compositions
JP2008518666A (ja) 生物活性創傷包帯および移植可能な装置ならびに使用法
JP4205592B2 (ja) 心臓組織修復を促進するためのトロンビン由来ペプチド
JP2001131086A (ja) エンドセリンを含む結合組織修復促進組成物および該組成物の調製におけるエンドセリンの使用
AU2002241917B2 (en) Thrombin derived peptides for promoting cardiac tissue repair
HK1060302B (en) Methods of therapy with thrombin derived peptides
AU2002241917A1 (en) Thrombin derived peptides for promoting cardiac tissue repair
HK1078263B (en) Thrombin derived peptides for promoting cardiac tissue repair
JP2001122799A (ja) プレイオトロフィンを含む結合組織修復促進組成物および該組成物の調製におけるプレイオトロフィンの使用
WO2011031476A2 (en) Compositions and methods for treatment or prevention of post-operative organ or tissue inflammation
KR20240155186A (ko) 혈관 내 스텐트용 생체모방 코팅
TAXI et al. Jamila CHEDLY1, Sylvia SOARES1, Alexandra MONTEMBAULT2, Ysander von BOXBERG1, Michèle VERON-RAVAILLE1, Christine MOUFFLE1, Marie-Noelle BENASSY1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060302

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: OSOLUGIAIS CO., LTD.

Free format text: FORMER OWNER: THE BOARD OF REGENTS, THE UNIV. OF TEXAS SYSTEM

Effective date: 20051223

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20051223

Address after: Arizona, USA

Applicant after: Orthologic Corp.

Address before: American Texas

Applicant before: Board of Regents of the Univ. of Texas System

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1060302

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090617

Termination date: 20130712